MRKR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient trader: no Intellectia signals, weak/soft technical tone, and no near-term news catalysts to drive an upside break.", "Price (1.76) is below the pivot (1.836) and showing bearish momentum (negative MACD), making a quick upside move less likely without a catalyst.", "Analyst upside ($10 PT) exists, but it\u2019s based on a single initiation and is not being reinforced by recent upgrades/news flow; near-term trading setup remains unattractive."]
["Trend/Momentum: MACD histogram is negative (-0.034) and still below zero (bearish), though the negative pressure is contracting (selling pressure easing, but not reversed).", "RSI(6) ~48.8 (neutral): no oversold bounce signal; momentum is not strong enough to justify an impatient entry.", "Moving averages are converging: indicates indecision/transition rather than a confirmed uptrend\u2014no clear trend-following buy setup.", "Key levels: Pivot 1.836 overhead; resistance at 2.053 then 2.188. Supports at 1.618 then 1.483. At 1.76, the stock is closer to support than resistance, but not at a clear 'washed-out' level.", "Pattern-based short horizon odds: modest positive bias next week (+6.37%) but negative bias over the next month (-1.58%), suggesting any strength may be choppy and not sustained."]
["Analyst coverage initiated with Buy and a $10 price target (H.C. Wainwright), highlighting potential of MAR-T platform across cancer immunotherapy.", "MACD bearish momentum is contracting, which sometimes precedes stabilization if buyers step in near support."]
["No news in the recent week: lack of fresh catalysts reduces probability of a near-term breakout for an impatient buyer.", "Intellectia Proprietary Trading Signals: - AI Stock Picker: no signal on given stock today; - SwingMax: No signal on given stock recently.", "Current tape is weak: regular market -2.20% and pre-market -3.62% (short-term pressure).", "Smart-money activity is not supportive: Hedge funds neutral (no significant trend last quarter); insiders neutral (no significant trend last month).", "No recent congress trading data available (no political/influential buying/selling signal)."]
["Latest quarter: 2025/Q3.", "Revenue: 1,232,938, down -35.99% YoY (deteriorating top-line trend).", "Net income: -1,998,662 (loss), down -13.41% YoY (losses persist).", "EPS: -0.12, down -53.85% YoY (earnings trend worsening).", "Gross margin: 100 (reported as unchanged YoY), but overall fundamentals still reflect a loss-making profile and declining revenue."]
["Recent trend: limited data\u2014single notable event is a 2025-12-08 initiation by H.C. Wainwright with a Buy rating and $10 PT; no subsequent upgrades/downgrades provided.", "Wall Street pros: differentiated non-genetically engineered T-cell approach (MAR-T), potential safety/efficacy/scalability advantages, and pipeline breadth (autologous/allogeneic).", "Wall Street cons (from the data context): financial performance is weakening (revenue down sharply, losses persist), and there are no near-term catalysts/news to help close the gap to the optimistic price target."]
